GTx files toremifene in US for bone fractures
This article was originally published in Scrip
GTx has submitted a US NDA for its oral selective oestrogen receptor modulator (SERM), toremifene 80mg, for the prevention of bone fractures in men with prostate cancer who are receiving androgen deprivation therapy (ADT).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.